Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.62 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21096442 | 0.86 | BRAF (0.56) | BRAFCYP3A4CYP2C9MAP3K20 | |
| SCHEMBL21046856 | 0.85 | BRAF (0.70) | BRAFMAP3K20 | |
| SCHEMBL21046931 | 0.85 | BRAF (0.57) | BRAFCYP3A4CYP2C9MAP3K20 | |
| SCHEMBL21046888 | 0.84 | BRAF (0.68) | BRAFMAP3K20 | |
| SCHEMBL21046838 | 0.84 | BRAF (0.70) | BRAFMAP3K20 | |
| SCHEMBL21047001 | 0.83 | BRAF (0.67) | BRAFMAP3K20 | |
| SCHEMBL21046790 | 0.82 | BRAF (0.60) | BRAFSLC40A1MAP3K20GLO1 | |
| SCHEMBL21046897 | 0.81 | BRAF (0.70) | BRAFCYP3A4CYP2C9MAP3K20 | |
| SCHEMBL21047095 | 0.80 | BRAF (0.69) | BRAFMAP3K20 | |
| SCHEMBL28075141 | 0.80 | BRAF (0.68) | BRAFMAP3K20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498693-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-30 | — | — | EP | disclosed |
| US-10696651-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10696651-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-30 | — | — | US | disclosed |
| EP-3498693-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-06 | — | — | US | disclosed |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696651-B2 | Heterocyclic compound | EIF2AK4, GCN1, GTF2I | BRAF 1618/4885SLC40A1 1390/4885CYP3A4 4156/4885 |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | EIF2AK4, GCN1, GTF2I | BRAF 1618/4885SLC40A1 1390/4885CYP3A4 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.